Traders should monitor Q2 2026 for the start of product revenue from DARE to PLAY and Flora Sync LF5. While the cash runway appears sufficient for now, the company's reliance on third parties and unproven commercial execution introduces risk. Positive early revenue or partnership announcements could catalyze upside.
Price Chart
Executive Summary
Daré Bioscience reported its 2025 financial results, highlighting a significant reduction in R&D expenses due to $16.4M in grant-funded contra-expenses, while maintaining a cash position of $24.7M. The company emphasized its commercial launch strategy for DARE to PLAY sildenafil cream and other women's health products, with product revenue expected to begin in Q2 2026. However, core operating losses remain high, and near-term revenue is still anticipated rather than realized.
Key Financial Metrics
Key Facts
- Daré reported $1.03M in license fee and other revenue for 2025, up from $9.8K in 2024.
- R&D expenses dropped to $5.5M in 2025 from $14.3M in 2024, largely due to $16.4M in grant-funded contra-R&D expenses.
- Cash and cash equivalents were $24.7M as of December 31, 2025, up from $15.7M in 2024.
- Net loss narrowed to $13.4M in 2025 from $4.1M in 2024, despite lower operating expenses.
- Product revenue from DARE to PLAY and Flora Sync LF5 is expected to begin in Q2 2026, but no commercial sales were recorded in 2025.
- The company relies heavily on third parties for manufacturing, dispensing, and telehealth access, introducing execution risk.
Financial Impact
Revenue increased to $1.03M (from $9.8K) but remains minimal; R&D costs were reduced by grant funding, masking underlying cash burn. True R&D investment was higher when grants are excluded.
Risk Factors
- Execution risk in launching and scaling DARE to PLAY through third-party pharmacy and telehealth partners.
- Continued reliance on non-dilutive funding to sustain R&D; future capital needs may lead to dilution.
- No FDA-approved products; revenue remains speculative until commercial sales are confirmed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263382 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 19d ago | DEF 14A | $0.7900 $0.7720 | ▲ +2.28% | ▲ +1.86% | $0.6467 (+18.14%) |
Oct 1, 2026 25d ago | 8-K | $0.8510 $0.8428 | ▼ −0.96% | ▼ −1.70% | $0.6467 (−24.01%) |
Sep 9, 2026 6w ago | 8-K | $0.7166 $0.7051 | ▼ −1.60% | ▼ −1.01% | $0.6467 (−9.75%) |
Sep 4, 2026 7w ago | EFFECT | $0.7210 $0.7130 | ▲ +1.11% | ▲ +0.56% | $0.6467 (+10.31%) |
Aug 17, 2026 10w ago | 8-K | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 17, 2026 10w ago | 424B5 | $0.8102 $0.7682 | ▲ +5.18% | ▲ +4.51% | $0.6467 (+20.18%) |
Aug 13, 2026 10w ago | 8-K | $0.9300 $0.8102 | ▼ −12.88% | ▼ −12.41% | $0.6467 (−30.46%) |
Aug 6, 2026 11w ago | Press Release | $1.33 $1.40 | ▲ +5.26% | ▲ +4.65% | $0.6467 (−51.38%) |
Jul 24, 2026 13w ago | 8-K | $1.28 $1.32 | ▲ +3.13% | ▲ +3.10% | $0.6467 (−49.48%) |
Jul 13, 2026 15w ago | 8-K | $2.09 $2.07 | ▼ −0.96% | ▼ −1.31% | $0.6467 (−69.06%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers